Dated values

Markdown

HSA post-marketing vigilance guidance Version 6

Final

HSA uploaded Version 6 of the post-marketing vigilance guidance on 1 April 2026, revising scope, contact requirements, serious-adverse-event criteria, identifiable-patient examples, literature reports, lack-of-efficacy reports, clinical safety study reports and eCTD submission references guidance revision

Reference period
Version 6 uploaded 1 April 2026
Population
Companies responsible for post-marketing surveillance of therapeutic products and CTGTP in Singapore
Denominator
Guidance scope; not a marketing-authorisation decision and not a declaration that every adverse event is reportable
Geography
Singapore

Record details

Published
2026-04-01
Metric
revision
Source revision
HSA Guidance Version 6

Dates describe this record’s own period and applicability. A verification date does not mean a rule is currently in force.

Sources

  1. https://isomer-user-content.by.gov.sg/409/a6db49dc-ed7f-4e44-93ad-7fb906e7d2f8/Guidance%20for%20Industry_Post-marketing%20Vigilance%20Requirements%20for%20Therapeutic%20Products%20and%20CTGTP_V.pdf Accessed

Collection as of 2026-11-22 · An expanding collection. Published counts show available knowledge, not complete coverage of Singapore. Machine-readable: JSON · sgobs.healthcare.hsa-post-marketing-vigilance-guidance-2026.revision